ITERUM THERAPEUTICS PLC (ITRM)

Company Profile

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 14 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The company is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. The company has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Company Info

ITERUM THERAPEUTICS PLC

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2

DUBLIN DUBLIN 2

P: 35316694820

CEO: Corey N. Fishman

Employees: 14

Website: https://www.iterumtx.com/